Contraline Secures $92.5 Million In Series B Funding Led By BVF Partners And RA Capital Management
Contraline, a Charlottesville-based clinical-stage biopharmaceutical company focused on male reproductive health, has raised $92.5 million in a Series B round co-led by BVF Partners L.P. and RA Capital Management , wi…
Contraline, a Charlottesville-based clinical-stage biopharmaceutical company focused on male reproductive health, has raised $92.5 million in a Series B round co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. The company said proceeds will advance late-stage development of NES/T Gel, a once-daily, reversible hormonal male contraceptive that recently completed a Phase 2b study and is expected to move toward Phase 3 trials in 2027. Co-founder and CEO Kevin Eisenfrats said the financing supports Contraline’s mission to expand contraceptive options for men and couples, as the company also continues development of its non-hormonal ADAM™ program.
FOUNDERS: Kevin Eisenfrats & Dr. John Herr
INVESTORS: BVF Partners L.P., RA Capital Management, GV (Google Ventures), Lumira Ventures & Invus
ROUND: Series B AMOUNT: $92,500,000
HQ: Charlottesville, Virginia
#VentureCapital #Contraline #KevinEisenfrats #DrJohnHerr #TradedVC
ABOUT THE DEAL
- Raise
- $93M
- Round
- Series B
- Company
- Contraline
- Desk
- Deals
- Filed
- Jun 3, 2026
- Founders
- Kevin Eisenfrats
- Dr. John Herr
- Investors
- BVF Partners L.P.
- RA Capital Management
- GV (Google Ventures)
- Lumira Ventures
- Invus
